Castle Biosciences Announces Updates to its Board of Directors
27 Março 2024 - 6:00PM
Business Wire
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving
health through innovative tests that guide patient care, today
announced that Rodney Cotton has been appointed to its board of
directors, effective immediately, and will stand for election at
Castle’s 2024 Annual Meeting of Stockholders, expected to be held
in May 2024. The Company further announced that Mara G. Aspinall
will not stand for re-election to its board, and her current term
will expire at the 2024 Annual Meeting. Aspinall has served on the
Company’s board since 2015.
“Mara has been a great partner and contributor,” said Derek
Maetzold, director, president and chief executive officer of Castle
Biosciences. “We thank her for her dedicated service to Castle.
“Rod’s broad range of leadership experience in the diagnostic
industry will be a significant benefit to our board. We are pleased
to welcome him.”
Cotton (age 64) is a leader in the diagnostics industry who is
known for his holistic perspective, bias for action in the face of
challenges and commitment to agile processes. He built a successful
career at Roche spanning more than two decades and culminating in
the role of senior vice president, head of strategy &
transformation, and chief of staff to the CEO for Roche
Diagnostics, the North American headquarters of the world's largest
diagnostics company. While at Roche, Cotton led key enterprise
initiatives, such as milestone corporate communications, health
equity coalitions, the U.S./Roche Group audit, and global/U.S.
acquisition integrations. With 40-plus years of experience, he
drove the financial turnaround and cultural transformation of four
global healthcare companies, led teams of up to 280 total reports,
managed a P&L of more than $1 billion in revenue, and served as
a key member of the senior leadership team executing the most
significant restructuring of the company in two decades. In the
face of the COVID-19 pandemic, Cotton and his team at Roche
accelerated six ground-breaking products in 11 months, including
the first launch of the market's most accurate and in-demand
molecular diagnostic test. He also solved challenges of product
scarcity, supply chain, product allocation, and logistics to
achieve accelerated global sourcing and self-manufacturing in line
with testing guidelines. He received The Sagamore of the Wabash
Award, one of the highest Indiana State honors, bestowed by Indiana
Governor Eric J. Holcomb.
Cotton currently serves on the board of directors of Eisai
Pharmaceutical U.S., a research and development pharmaceutical
company and subsidiary of Eisai Company, Ltd., Orchard Software, a
private equity-backed health technology company owned by Francisco
Partners; an advisory board member to Flo2 Ventures, a venture
capital-backed healthcare and health equity accelerator; and serves
as a member of the board of directors and on three board committees
(Audit, Compliance & Finance; Governance & Equity; and
Quality of Care) for Community Health Network.
Cotton holds an MBA from California State University, Dominguez
Hills, an M.S. in strategic management from the University of
Southern California, and a B.A. in biological sciences &
technology from the University of California at Santa Barbara.
With Cotton’s addition, the Company’s board will be comprised of
nine directors, five of whom have been appointed in the past four
years.
About Castle Biosciences Castle Biosciences (Nasdaq:
CSTL) is a leading diagnostics company improving health through
innovative tests that guide patient care. The Company aims to
transform disease management by keeping people first: patients,
clinicians, employees and investors.
Castle’s current portfolio consists of tests for skin cancers,
Barrett’s esophagus, mental health conditions and uveal melanoma.
Additionally, the Company has active research and development
programs for tests in other diseases with high clinical need,
including its test in development to help guide systemic therapy
selection for patients with moderate-to-severe atopic dermatitis,
psoriasis and related conditions. To learn more, please visit
www.CastleBiosciences.com and connect with us on LinkedIn,
Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath
Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM,
DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle
Biosciences, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240327305125/en/
Investor Contact: Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact: Allison Marshall
amarshall@castlebiosciences.com
Castle Biosciences (NASDAQ:CSTL)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Castle Biosciences (NASDAQ:CSTL)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024